Effect of intensive intervention on risk factors of cardiac metabolism on prognosis of coronary atherosclerotic heart disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067082

Enrollment

Unknown

Registered

2022-12-26

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Intensive therapy group:Intensive drug therapy: blood pressure controlled to 110-130/60-80mmHg

Routine treatment group:Routine treatment: BP < 140/90mmHg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age = 18 years; (2) Outpatients/inpatients with coronary artery CTA and clinical diagnosis of coronary heart disease; (3) At least the following cardiac metabolic risk factors should be met. The specific diagnostic criteria were: ? Hypertension: without the use of antihypertensive drugs, the blood pressure in the consulting room was measured three times on different days, SBP = 140 mmHg and/or DBP = 90 mmHg; Patients with hypertension who are taking antihypertensive drugs. ? Lipid needs intervention: those with LDL cholesterol = 1.8mmol/L or taking lipid-lowering drugs. ? Abnormal glucose metabolism: impaired fasting glucose (IFG) FPG is between 6.1-7.0mmol/L, 2-hour PG<7.8mmol/L or abnormal glucose tolerance (IGT) FPG is<7.0mmol/L, 2-hour PG is between 7.8-11.1mmol/L; People with diabetes who are taking antidiabetic drugs. (4) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant women or women who are going to be pregnant in the next two years; (2) Patients with life expectancy less than 1 year; (3) Severe liver and kidney dysfunction (ALT>5 times ULA eGFR<15ml/min/1.73mm2); (4) Type 1 diabetes patients; (5) Known active malignant tumor diseases; (6) The investigator believes that the patient is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
Comparison of coronary CTA results;	—

Secondary

Measure	Time frame
MACE event:Recurrent angina pectoris;MACE event: Acute myocardial infarction;MACE event: severe arrhythmia;MACE event: Heart failure;MACE event: Death of coronary heart disease;	—

Countries

China

Contacts

Public ContactYue Jingwen

Tongren Hospital Affiliated to Shanghai Jiaotong University School of Medicine

yjw_1119@shsmu.edu.cn+86 13611875736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026